Part 1 Overview of Dengue What Is Dengue Prevalence of Dengue in Latin America Dengue Reported Cases in the Americas 2016 to 2017 Dengue Serotypes Limitations of Dengue Surveillance Dengue Pathophysiology and Disease Severity ID: 697147
Download Presentation The PPT/PDF document "Dengue Prevention in Latin America" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Dengue Prevention in Latin AmericaSlide2
Part 1: Overview of DengueSlide3
What Is Dengue?Slide4
Prevalence of Dengue in Latin AmericaSlide5
Dengue Reported Cases in the Americas, 2016 to 2017Slide6
Dengue SerotypesSlide7
Limitations of Dengue SurveillanceSlide8
Dengue Pathophysiology and Disease SeveritySlide9
Economic Costs of Symptomatic Dengue InfectionSlide10
Getting Dengue More Than OnceSlide11
Why Severe Dengue Occurs Slide12
Prevention of Dengue: WHO StrategySlide13
Dengue CYD-TDVSlide14
VE in Individuals Aged 9 to 16 YearsSlide15
Safety and Efficacy of CYD15 (Latin America)Slide16
Part 2: Dengue Q&ASlide17
Question: Why is the dengue vaccine not recommended in children aged < 9 years? Slide18
Differences in VE According to Age and Baseline SerostatusSlide19
Efficacy of CYD-TDV Slide20
Question: What did the WHO recommend in July 2016 for countries considering introducing the CYD-TDV vaccine?Slide21
WHO Recommendation, July 2016Slide22
Question: What did the additional analysis provided to WHO conclude?Slide23
Results of Additional Analysis of Dengue Vaccine DataSlide24
Question: Why is there a higher risk for severe dengue in seronegative people who receive the vaccine?Slide25
Higher Severe Dengue Risk in Seronegative People Who Receive the VaccineSlide26
Higher Severe Dengue Risk in Seronegative People Who Receive the Vaccine (cont)Slide27
Question: What happens to people who have breakthrough dengue after being vaccinated?Slide28
Breakthrough Dengue After VaccinationSlide29
Question: Has the WHO updated its position as a result of this analysis?Slide30
WHO Position, December 2017Slide31
WHO Position, December 2017 (cont)Slide32
Question: Why did the vaccine manufacturer request a label update in November 2017?Slide33
Vaccine Label Update RequestSlide34
Question: Are people previously infected with dengue likely to know that they had the disease?Slide35
Awareness of Previous Dengue InfectionSlide36
Question: How can a physician determine whether or not a patient should receive the vaccine?Slide37
Deciding Whether to VaccinateSlide38
Questions from patients and parentsSlide39
Considerations When Vaccinating ChildrenSlide40
Other ConsiderationsSlide41
SummarySlide42